DTech Liquidating

DTech Liquidating Liabilities

Delisted

The The Liabilities of DTech Liquidating (DMTKQ) as of Nov 21, 2026 is 64.76 M USD. In the previous year, The Liabilities was 69.70 M USD — a change of -7.09% (lower).

Liabilities

64.76 MUSD

YoY

-7.09%

Last updated:

In 2023, DTech Liquidating's total liabilities amounted to 64.76 M USD, a -7.09% difference from the 69.70 M USD total liabilities in the previous year.

The DTech Liquidating Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2016
200,000.00 USD
Jan 1, 2017
5.10 M USD
Jan 1, 2018
6.60 M USD
Jan 1, 2019
5.70 M USD
Jan 1, 2020
6.30 M USD
Jan 1, 2021
18.60 M USD
Jan 1, 2022
69.70 M USD
Jan 1, 2023
64.76 M USD
The DTech Liquidating Liabilities history
YEARLiabilitiesYoY
64.76 MUSD-7.09%
69.70 MUSD+274.73%
18.60 MUSD+195.24%
6.30 MUSD+10.53%
5.70 MUSD-13.64%
6.60 MUSD+29.41%
5.10 MUSD+2,450.00%
200,000.00USD+100.00%
100,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing DTech Liquidating's Liabilities

DTech Liquidating's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating DTech Liquidating's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing DTech Liquidating's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

DTech Liquidating's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in DTech Liquidating’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about DTech Liquidating stock

The Liabilities of DTech Liquidating is 64.76 M USD in 2023.

The Liabilities of DTech Liquidating changed from 69.70 M USD to 64.76 M USD, representing a -7.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's DTech Liquidating historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — DTech Liquidating

All Key Metrics — DTech Liquidating